New Insights Into Antimicrobial Resistance (AMR)
- Findings challenge the traditional view that antimicrobial resistance (AMR) emerges from pathogens that acquire new mutations
- Samples from ICU patients suggest that instead, highly diverse pathogen communities harbor pre-existing resistant genotypes
- The results suggest that interventions aimed at limiting the spread of bacteria between patients may provide a powerful approach to combat AMR.
A research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings, published today in the journal Nature Communications, could help develop more effective interventions to prevent AMR infections developing in vulnerable patients.
The study’s findings challenge the traditional view that people are generally infected by a single genetic clone (or ‘strain’) of pathogenic bacteria, and that resistance to antibiotic treatment evolves because of natural selection for new genetic mutations that occur during the infection. The results suggest that instead patients are commonly co-infected by multiple pathogen clones, with resistance emerging as a result of selection for pre-existing resistant clones, rather than new mutations.
The researchers used a novel approach that studied changes in the genetic diversity and antibiotic resistance of a pathogenic bacteria species (Pseudomonas aeruginosa) collected from patients before and after antibiotic treatment. The samples were isolated from 35 intensive care unit (ICU) patients in 12 European hospitals. Pseudomonas aeruginosa is an opportunistic pathogen that is an important cause of hospital-acquired infections, particularly in immunocompromised and critically ill patients, and is thought to cause more than 550,000 deaths globally each year.
Each patient was screened for Pseudomonas aeruginosa soon after being admitted to ICU, with samples then collected at regular intervals thereafter. The researchers used a combination of genomic analyses and antibiotic challenge tests to quantify within-patient bacterial diversity and antibiotic resistance.
Single-Strain vs. Multi-Strain Infections
Most patients in the study (approximately two-thirds) were infected by a single Pseudomonas strain. AMR evolved in some of these patients due to the spread of new resistance mutations that occurred during infection, supporting the conventional model of resistance acquisition. Surprisingly, the authors found that the remaining third of patients were actually infected by multiple strains of Pseudomonas.
Crucially, resistance increased by about 20% more when patients with mixed strain infections were treated with antibiotics, compared to patients with single strain infections. The rapid increase in resistance in patients with mixed-strain infections was driven by natural selection for pre-existing resistant strains that were already present at the onset of antibiotic treatment. These strains usually made up a minority of the pathogen population that was present at the start of antibiotic treatment, but the antibiotic resistance genes that they carried gave them a strong selective advantage under antibiotic treatment.
However, although AMR emerged more quickly in multi-strain infections, the findings suggest it may also be lost more rapidly in these conditions. When samples from single-strain and mixed-strain patients were cultured in the absence of antibiotics, the AMR strains grew more slowly compared with non-AMR strains. This supports the hypothesis that AMR genes carry fitness trade-offs, such that they are selected against when no antibiotics are present. These trade-offs were stronger in mixed-strain populations than in single-strain populations, suggesting that within-host diversity can also drive the loss of resistance in the absence of antibiotic treatment.
Implications for AMR Prevention Strategies
According to the researchers, the findings suggest that interventions aimed at limiting the spread of bacteria between patients (such as improved sanitation and infection control measures) may be a more effective intervention to combat AMR than interventions that aim to prevent new resistance mutations arising during infection, such as drugs that decrease the bacterial mutation rate. This is likely to be especially important in settings where the infection rate is high, such as patients with compromised immunity.
The findings also suggest that clinical tests should move towards capturing the diversity of pathogen strains present in infections, rather than testing for only a small number of pathogen isolates (based on the assumption that the pathogen population is effectively clonal). This could enable more accurate predictions of whether antibiotic treatments will succeed or fail in individual patients, similar to how measurements of diversity in cancer cell populations can help predict the success of chemotherapy.
Lead researcher Professor Craig Maclean, from the University of Oxford’s Department of Biology, said: “The key finding of this study is that resistance evolves rapidly in patients colonized by diverse Pseudomonas aeruginosa populations due to selection for pre-existing resistant strains. The rate at which resistance evolves in patients varies widely across pathogens, and we speculate that high levels of within-host diversity may explain why some pathogens, such as Pseudomonas, rapidly adapt to antibiotic treatment.”
He added: “The diagnostic methods that we use to study antibiotic resistance in patient samples have changed very slowly over time, and our findings underscore the importance of developing new diagnostic methods that will make it easier to assess the diversity of pathogen populations in patient samples.”
The World Health Organization has declared AMR to be one of the top 10 global public health threats facing humanity. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to medicines such as antibiotics, making infections increasingly difficult or impossible to treat. Of particular concern is the rapid spread of multi-resistant pathogenic bacteria, that cannot be treated with any existing antimicrobial medicines. In 2019, AMR was associated with nearly 5 million deaths worldwide.
Professor Willem van Schaik, Director of the Institute of Microbiology and Infection at the University of Birmingham (who was not directly involved with the study) said: “This study strongly suggests that clinical diagnostic procedures may need to be expanded to include more than one strain from a patient, to accurately capture the genetic diversity and antibiotic resistance potential of strains that colonize critically ill patients. It also highlights the importance of ongoing infection prevention efforts that aim to reduce the risk of hospitalized patients being colonized, and subsequently infected, by opportunistic pathogens during their hospital stay.”
Sharon Peacock, Professor of Microbiology and Public Health at the University of Cambridge (who was not directly involved with the study), said: “Multidrug-resistant infections caused by a range of organisms including Pseudomonas aeruginosa are a major challenge for patient management in ICU settings worldwide. The findings of this study add further evidence for the vital importance of infection prevention and control measures in ICUs and hospital settings more widely that reduce the risk of acquiring P. aeruginosa and other pathogenic organisms.”
Reference: “Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients” by Julio Diaz Caballero, Rachel M. Wheatley, Natalia Kapel, Carla López-Causapé, Thomas Van der Schalk, Angus Quinn, Liam P. Shaw, Lois Ogunlana, Claudia Recanatini, Basil Britto Xavier, Leen Timbermont, Jan Kluytmans, Alexey Ruzin, Mark Esser, Surbhi Malhotra-Kumar, Antonio Oliver and R. Craig MacLean, 12 July 2023, Nature Communications.
DOI: 10.1038/s41467-023-39416-2
The patients who provided samples for the study were participants in the Advanced understanding of Staphylococcus aureus and Pseudomonas aeruginosa Infections in EuRopE – Intensive Care Units (ASPIRE-ICU) trial. This study, nested within routine surveillance of ICU patients in Europe aims to improve understanding of Staphylococcus aureus and Pseudomonas aeruginosa infections in Europe.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.